Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q4 2010

Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Chronic Myelocytic Leukemia Pipeline Review, Q4 2010”, provides an overview of the Chronic Myelocytic Leukemia therapeutic pipeline. This report provides information on the therapeutic development for Chronic Myelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia. “Chronic Myelocytic Leukemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Chronic Myelocytic Leukemia.
- A review of the Chronic Myelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Myelocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Chronic Myelocytic Leukemia.
- A review of the Chronic Myelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Myelocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Myelocytic Leukemia (CML) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Myelocytic Leukemia (CML)
Chronic Myelocytic Leukemia (CML) Therapeutics under Development by Companies
Chronic Myelocytic Leukemia (CML) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chronic Myelocytic Leukemia (CML) Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Abbott Laboratories
Bioniche Life Sciences, Inc.
Merck & Co., Inc.
Micromet, Inc.
Bio-Path Holdings, Inc.
BioSante Pharmaceuticals, Inc.
Novartis AG
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Sunesis Pharmaceuticals, Inc.
Astex Therapeutics Limited
Celgene Corporation
Vernalis plc
AEterna Zentaris Inc.
Lorus Therapeutics Inc
ChemGenex Pharmaceuticals Limited
TopoTarget A/S
University of Glasgow
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Innate Pharma SA
Piramal Life Sciences Limited
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
Eisai Inc.
Abiogen Pharma S.p.A.
ViroStatics, srl
S-BIO Pte Ltd
Deciphera Pharmaceuticals, LLC
Onconova Therapeutics, Inc
Globeimmune, Inc.
Cylene Pharmaceuticals, Inc.
Targa Therapeutics Corp.
Mayo Clinic
Universities/Institutes Involved in Chronic Myelocytic Leukemia (CML) Therapeutics Development
Chronic Myelocytic Leukemia (CML) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Bosutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GVAX Immunotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon-alpha + Cytosine arabinoside - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LBH589 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMAPRO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tasigna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tiazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
5-Azacytidin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dactinomycin + sargramostim + CHOP regimen + carmustine + cyclophosphamide + cytarabine + daunorubicin hydrochloride + doxorubicin hydrochloride + etoposide + mercaptopurine + methotrexate + mitoxantrone hydrochloride + pegaspargase + prednisone + vincris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Homoharringtonine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + AraC + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + Recombinant Interferon Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon alfa + ARA-C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon alfa + ARA-C + Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alpha + Hydroxyurea + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon-alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
recombinant interferon alfa + busulfan + cytarabine + hydroxyurea + idarubicin + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Interferon Alfa + Cytarabine + Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sprycel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 + Peg-Interferon-Alpha2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 600 mg - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thymoglobulin for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Umbilical Cord Blood Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Chronic Myelocytic Leukemia (CML) - Featured News
Dec 06, 2010: Pfizer Announces Phase III Results Of Bosutinib In Patients With Newly Diagnosed Chronic Myeloid Leukemia
Dec 06, 2010: ChemGenex Presents Updated Analysis On OMAPRO In Chronic Myeloid Leukemia Patients At ASH
Dec 06, 2010: ARIAD's Ponatinib Shows Clinical Evidence Of Improving Anti-Leukemic Activity In Patients With Drug-Resistant Chronic Myeloid Leukemia
Dec 06, 2010: Novartis Reports Longer-Term Phase III Data Of Tasigna In Chronic Myeloid Leukemia
Dec 04, 2010: ARIAD's Ponatinib Shows Clinical Evidence Of Improving Anti-Leukemic Activity In Drug-Resistant CML
Dec 03, 2010: Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
Dec 03, 2010: Onconova To Present Clinical Trials Update For Estybon At ASH Annual Meeting
Dec 01, 2010: Stemline To Present Clinical and Pre-Clinical Efficacy Data On SL-401 At Annual Meeting of American Society Of Hematology
Nov 29, 2010: ARIAD To Present Updated Clinical Data On AP24534 At ASH Annual Meeting
Oct 14, 2010: BMS And Ostuka Launch My SPRYCEL Support Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer